Does ICER Promote Discriminatory Drug Pricing Based on Its Analytics Methods?

Jun 29, 2019 | Aging, Discrimination, Drug Pricing, ICER, Price Fixing, Price Watch, Pricing

Elderly Discrimination

A nonprofit known as Alliance for Aging Research has put out a fact sheet suggesting ICER research analytics be questioned on grounds that it supports discriminatory drug pricing.  

What follows are some key points to consider:

  • ICER produces reports known as “comparative effectiveness research” on how it thinks new drugs should cost.
  • ICER metrics value treating young individuals in good health as more cost-effective than treating older adults (65 and older) or people with disabilities
  • Insurance companies use these values to decide whether its worth paying for a certain treatment or test
  • Sick and older patients are more likely to be denied access to medications that could help improve their condition or quality of life

Follow the link below to learn more about ICER from the Alliance for Aging Research perspective. TrialSite News provides more information about the Alliance for Aging Research.

Alliance for Aging Research (AAR) Background

A non-profit advocacy group founded in 1986, they seek to influence policy to champion causes for the elderly. They were founded by Daniel Perry and include a board of directors and a scientific advisory board. Their CEO is Susan Peschin.

AAR’s main policy focus has been aging research funding, FDA funding, stem cell research funding and improving health care for older Americans. They seek to hold congressional briefings to increase awareness of such diseases and conditions such as osteoporosis, Alzheimer’s disease, oral care and diabetes.

They also are aligned with a number of coalitions and committees such as Friends of the National Institute on Aging (NIA), the Alliance for a Stronger FDA, Coalition for the Advancement of Medical Research (CAMR), Partnership to Fight Chronic Disease and the National Coalition on Mental Health and Aging.

An Issue to Monitor

ICER has described why some of their core underlying analytical principles such as QALY are the gold standard for determining fair price for drugs. A deep analysis herein is not the time nor the place. However, TrialSite News will continue to monitor this topic. Elderly Americans spend their lives paying taxes and contributing to the society. Their lives are as valuable now as they were when they were young. Any analysis of drug pricing must consider that each and every life is as valuable as any other.


Pin It on Pinterest